← Back to Search

PD-1 Inhibitor

RBN-2397 + Pembrolizumab for Small Cell Lung Cancer

Phase 1 & 2
Waitlist Available
Led By Melissa Johnson, MD
Research Sponsored by Ribon Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion (an average of 6 months)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug, RBN-2397, along with pembrolizumab in patients with advanced lung cancer who have not responded to previous treatments. RBN-2397 helps stop cancer cells from hiding from the immune system, while pembrolizumab helps the immune system attack the cancer.

Eligible Conditions
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion (an average of 6 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion (an average of 6 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determine recommended Phase 2 dose (RP2D) (Phase 1b)
Overall Response Rate (Phase 2)
Secondary study objectives
AUC of RBN-2397
Cmax of RBN-2397
Safety determined by Treatment-Emergent Adverse Events
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: RBN-2397 in combination with pembrolizumabExperimental Treatment1 Intervention
RBN-2397 orally in combination with the fixed approved dose of IV pembrolizumab

Find a Location

Who is running the clinical trial?

Ribon Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
202 Total Patients Enrolled
Melissa Johnson, MDPrincipal InvestigatorTennessee Oncology
6 Previous Clinical Trials
883 Total Patients Enrolled

Media Library

Pembrolizumab (PD-1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05127590 — Phase 1 & 2
Lung Cancer Research Study Groups: RBN-2397 in combination with pembrolizumab
Lung Cancer Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT05127590 — Phase 1 & 2
Pembrolizumab (PD-1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05127590 — Phase 1 & 2
~13 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top